Skip to content
OpenCapital
Get started

Nuvation Bio NUVB JP — Revenue

Similar metrics at other companies

Kyndryl Holdings logo
KDJP — Revenue
$571M-3.1%
Oracle logo
ORCLJP — Revenue
$467.5M+6.3%
Universal Display logo
OLEDJP — Revenue
$371K-10.2%
AXT
AXTIJP — Revenue
$1.55M+115%
Aurinia Pharmaceuticals logo
AUPHJapan — Revenue
$4.8M-23.3%
Weyerhaeuser logo
WYJP — Revenue
$67.75M+5.0%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's jp — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's JP — revenue?
Nuvation Bio (NUVB) reported JP — revenue of $652K in Q1 2026.
How has Nuvation Bio's JP — revenue changed year-over-year?
Nuvation Bio's JP — revenue increased by 256.3% year-over-year, from $183K to $652K.
What does JP — revenue mean?
This metric represents the total gross income generated by the company from its operations within the Japan geographic segment. It reflects the company's ability to monetize its therapeutic candidates and commercial activities in this specific market. Tracking this figure helps investors assess the geographic diversification of the company's revenue streams and the adoption rate of its oncology portfolio in the Japanese market.